{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T17:47:19Z","timestamp":1792432039193,"version":"4.5.0"},"reference-count":15,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Chromatography B"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.jchromb.2025.124604","type":"journal-article","created":{"date-parts":[[2025,4,14]],"date-time":"2025-04-14T15:09:53Z","timestamp":1744643393000},"page":"124604","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Quantification of Ivacaftor, Tezacaftor, Elexacaftor, and Lumacaftor and their active metabolites in plasma using UHPLC-MS\/MS: Doors open to the application of therapeutic drug monitoring in cystic fibrosis treatment"],"prefix":"10.1016","volume":"1258","author":[{"given":"A. Mireille A.","family":"Wessels","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Femke A.","family":"Elzinga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerard H.","family":"Koppelman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Onno W.","family":"Akkerman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Mian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daan J.","family":"Touw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.jchromb.2025.124604_bb0005","doi-asserted-by":"crossref","first-page":"e72","DOI":"10.1016\/j.jcf.2021.04.005","article-title":"Pharmacokinetic interactions between ivacaftor and cytochrome P450 3A4 inhibitors in people with cystic fibrosis and healthy controls","volume":"20","author":"van der Meer","year":"2021","journal-title":"J. Cyst. Fibros."},{"issue":"10","key":"10.1016\/j.jchromb.2025.124604_bb0010","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1111\/bcp.13324","article-title":"The pharmacokinetic interaction between ivacaftor and ritonavir in healthy volunteers","volume":"83","author":"Liddy","year":"2017","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"11","key":"10.1016\/j.jchromb.2025.124604_bb0015","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1002\/ppul.26093","article-title":"Plasma and cellular ivacaftor concentrations in patients with cystic fibrosis","volume":"57","author":"Guimbellot","year":"2022","journal-title":"Pediatr. Pulmonol."},{"key":"10.1016\/j.jchromb.2025.124604_bb0020","author":"US Food and Drug Administration"},{"issue":"4","key":"10.1016\/j.jchromb.2025.124604_bb0030","doi-asserted-by":"crossref","first-page":"313","DOI":"10.2165\/00003088-199835040-00004","article-title":"Drug disposition in cystic fibrosis","volume":"35","author":"Rey","year":"1998","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.jchromb.2025.124604_bb0035","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.577263","article-title":"Insights into patient variability during Ivacaftor-Lumacaftor therapy in cystic fibrosis","volume":"12","author":"Hanafin","year":"2021","journal-title":"Front. Pharmacol."},{"issue":"2","key":"10.1016\/j.jchromb.2025.124604_bb0040","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s41030-020-00124-7","article-title":"Physiologically based pharmacokinetic modeling of CFTR modulation in people with cystic fibrosis transitioning from mono or dual regimens to triple-combination Elexacaftor\/Tezacaftor\/Ivacaftor","volume":"6","author":"Tsai","year":"2020","journal-title":"Pulm. Ther."},{"issue":"2","key":"10.1016\/j.jchromb.2025.124604_bb0045","doi-asserted-by":"crossref","first-page":"628","DOI":"10.3390\/biomedicines11020628","article-title":"Simultaneous quantification of Ivacaftor, Tezacaftor, and Elexacaftor in cystic fibrosis patients\u2019 plasma by a novel LC-MS\/MS method","volume":"11","author":"Pigliasco","year":"2023","journal-title":"Biomedicines"},{"key":"10.1016\/j.jchromb.2025.124604_bb0050","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.jchromb.2016.10.026","article-title":"Development of HPLC and LC-MS\/MS methods for the analysis of ivacaftor, its major metabolites and lumacaftor in plasma and sputum of cystic fibrosis patients treated with ORKAMBI or KALYDECO","volume":"1038","author":"Schneider","year":"2016","journal-title":"J. Chromatogr. B"},{"issue":"5","key":"10.1016\/j.jchromb.2025.124604_bb0055","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1021\/acsptsci.0c00103","article-title":"Multiple reaction monitoring mass spectrometry for the drug monitoring of Ivacaftor, Tezacaftor, and Elexacaftor treatment response in cystic fibrosis: a high-throughput method","volume":"3","author":"Reyes-Ortega","year":"2020","journal-title":"ACS. Pharmacol. Transl. Sci."},{"issue":"4","key":"10.1016\/j.jchromb.2025.124604_bb0060","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1097\/FTD.0000000000000829","volume":"43","author":"Vonk","year":"2021","journal-title":"Ther. Drug Monit."},{"issue":"1","key":"10.1016\/j.jchromb.2025.124604_bb0065","first-page":"82","article-title":"Isotope dilution LC-MS\/MS quantification of the cystic fibrosis transmembrane conductance regulator (CFTR) modulators ivacaftor, lumacaftor, tezacaftor, elexacaftor, and their major metabolites in human serum","volume":"60","author":"Halber","year":"2021","journal-title":"Clin. Chem. Lab. Med."},{"issue":"248","key":"10.1016\/j.jchromb.2025.124604_bb0070","article-title":"A rapid LC-MS\/MS method for the simultaneous quantification of ivacaftor, lumacaftor, elexacaftor, tezacaftor, hexyl-methyl ivacaftor, and ivacaftor carboxylate in human plasma","volume":"15","author":"Zheng","year":"2024","journal-title":"J. Pharm. Biomed. Anal."},{"issue":"26","key":"10.1016\/j.jchromb.2025.124604_bb0075","doi-asserted-by":"crossref","first-page":"5565","DOI":"10.1007\/s00216-024-05496-2","article-title":"Development and clinical implementation of an LC-MRMS method for ivacaftor, lumacaftor, tezacaftor and elexacaftor in human plasma and breast milk","volume":"416","author":"Hansson","year":"2024","journal-title":"Anal. Bioanal. Chem."},{"issue":"8","key":"10.1016\/j.jchromb.2025.124604_bb0080","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.3390\/pharmaceutics14081674","article-title":"Therapeutic drug monitoring of Ivacaftor, Lumacaftor, Tezacaftor, and Elexacaftor in cystic fibrosis: where are we now?","volume":"14","author":"Choong","year":"2022","journal-title":"Pharmaceutics"}],"container-title":["Journal of Chromatography B"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1570023225001564?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1570023225001564?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,30]],"date-time":"2025-04-30T04:19:42Z","timestamp":1745986782000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1570023225001564"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":15,"alternative-id":["S1570023225001564"],"URL":"https:\/\/doi.org\/10.1016\/j.jchromb.2025.124604","relation":{},"ISSN":["1570-0232"],"issn-type":[{"value":"1570-0232","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Quantification of Ivacaftor, Tezacaftor, Elexacaftor, and Lumacaftor and their active metabolites in plasma using UHPLC-MS\/MS: Doors open to the application of therapeutic drug monitoring in cystic fibrosis treatment","name":"articletitle","label":"Article Title"},{"value":"Journal of Chromatography B","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jchromb.2025.124604","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"124604"}}